Zura Bio (NASDAQ:ZURA) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Zura Bio (NASDAQ:ZURAFree Report) in a report published on Wednesday morning, MarketBeat.com reports. The brokerage issued an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Zura Bio’s FY2024 earnings at ($0.64) EPS.

Several other brokerages have also issued reports on ZURA. Piper Sandler began coverage on shares of Zura Bio in a research note on Friday, May 3rd. They issued an overweight rating and a $26.00 price target on the stock. Oppenheimer lifted their price target on shares of Zura Bio from $16.00 to $21.00 and gave the company an outperform rating in a research note on Friday, May 10th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of Buy and a consensus price target of $19.80.

Read Our Latest Research Report on ZURA

Zura Bio Price Performance

Shares of NASDAQ ZURA opened at $3.77 on Wednesday. The company’s fifty day moving average is $4.32 and its 200-day moving average is $3.99. Zura Bio has a twelve month low of $2.00 and a twelve month high of $13.00.

Zura Bio (NASDAQ:ZURAGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.21. Analysts expect that Zura Bio will post -0.51 EPS for the current year.

Insider Buying and Selling

In other Zura Bio news, Director Amit Munshi acquired 159,744 shares of the business’s stock in a transaction on Monday, April 22nd. The stock was purchased at an average price of $3.13 per share, with a total value of $499,998.72. Following the acquisition, the director now directly owns 777,384 shares of the company’s stock, valued at approximately $2,433,211.92. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Zura Bio news, Director Amit Munshi acquired 159,744 shares of the business’s stock in a transaction on Monday, April 22nd. The stock was purchased at an average price of $3.13 per share, with a total value of $499,998.72. Following the acquisition, the director now directly owns 777,384 shares of the company’s stock, valued at approximately $2,433,211.92. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Van Amstel Arnout Ploos acquired 80,000 shares of the business’s stock in a transaction on Friday, May 17th. The stock was acquired at an average cost of $6.20 per share, with a total value of $496,000.00. Following the acquisition, the director now directly owns 100,000 shares in the company, valued at $620,000. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 250,926 shares of company stock valued at $1,030,998. Company insiders own 15.80% of the company’s stock.

Institutional Trading of Zura Bio

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Forefront Analytics LLC lifted its holdings in shares of Zura Bio by 46.8% during the 4th quarter. Forefront Analytics LLC now owns 21,229 shares of the company’s stock worth $99,000 after acquiring an additional 6,765 shares during the period. Lynx1 Capital Management LP acquired a new position in Zura Bio during the 3rd quarter worth approximately $65,000. Bank of New York Mellon Corp acquired a new position in Zura Bio during the 3rd quarter worth approximately $224,000. Eisler Capital US LLC acquired a new position in Zura Bio during the 3rd quarter worth approximately $660,000. Finally, Armistice Capital LLC increased its position in Zura Bio by 15.4% during the 4th quarter. Armistice Capital LLC now owns 1,824,000 shares of the company’s stock worth $8,518,000 after purchasing an additional 244,000 shares in the last quarter. Institutional investors own 61.14% of the company’s stock.

About Zura Bio

(Get Free Report)

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.

Featured Stories

Analyst Recommendations for Zura Bio (NASDAQ:ZURA)

Receive News & Ratings for Zura Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zura Bio and related companies with MarketBeat.com's FREE daily email newsletter.